🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525790-39-00
Completed Phase I

A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.

2026-525790-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Glaxosmithkline Research & Development Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Bacterial Infections and Mycoses
Decision date
06/07/2026
Enrollment target
28
Sites
Spain

Condition studied

Tuberculosis

Eligibility

Age group
65+ years, 18-64 years
Sex
Female
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525790-39-00 on CTIS ↗ ← All trials in the EU